Teva Pharmaceutical Industries (TEVA) to Release Earnings on Wednesday

Teva Pharmaceutical Industries (NYSE:TEVA) is projected to release its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect Teva Pharmaceutical Industries to announce earnings of $0.08 per share and revenue of $4.0473 billion for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:00 AM ET.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The company had revenue of $3.98 billion for the quarter. On average, analysts expect Teva Pharmaceutical Industries to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Teva Pharmaceutical Industries Stock Up 1.1%

Shares of NYSE TEVA opened at $31.36 on Wednesday. The stock has a market capitalization of $36.05 billion, a P/E ratio of 23.58, a PEG ratio of 3.27 and a beta of 0.86. The stock’s fifty day moving average is $33.57 and its 200 day moving average is $32.70. Teva Pharmaceutical Industries has a 52 week low of $14.99 and a 52 week high of $37.35. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on TEVA shares. Bank of America increased their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 9th. Barclays upped their price target on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Truist Financial increased their price target on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Friday. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $41.78.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 144,180 shares of the company’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $34.99, for a total value of $5,044,858.20. Following the completion of the transaction, the insider owned 80,760 shares of the company’s stock, valued at $2,825,792.40. This represents a 64.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Amir Weiss sold 10,679 shares of the stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total value of $384,444.00. Following the completion of the transaction, the chief accounting officer owned 20,016 shares of the company’s stock, valued at $720,576. This represents a 34.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 465,931 shares of company stock worth $16,332,989 over the last 90 days. 0.54% of the stock is currently owned by company insiders.

Institutional Trading of Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Dorsey & Whitney Trust CO LLC acquired a new stake in Teva Pharmaceutical Industries during the 4th quarter worth approximately $262,000. Franklin Resources Inc. bought a new stake in Teva Pharmaceutical Industries during the 2nd quarter worth approximately $255,000. FAS Wealth Partners Inc. acquired a new position in Teva Pharmaceutical Industries in the 4th quarter valued at approximately $222,000. Advisors Asset Management Inc. increased its position in Teva Pharmaceutical Industries by 80.9% in the 4th quarter. Advisors Asset Management Inc. now owns 6,871 shares of the company’s stock valued at $214,000 after acquiring an additional 3,073 shares during the period. Finally, Peapack Gladstone Financial Corp bought a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at $174,000. 54.05% of the stock is currently owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.